Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

BACKGROUND: Eribulin methylate (eribulin) improved the overall survival (OS) of eribulin-treated patients with HER2-negative advanced breast cancer (ABC) in prospective and retrospective studies. However, the effect of eribulin on OS as first-line chemotherapy and the characteristics of the patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamoto, Shogo, Watanabe, Junichiro, Ohtani, Shoichiro, Morita, Satoshi, Ikeda, Masahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722338/
https://www.ncbi.nlm.nih.gov/pubmed/34980019
http://dx.doi.org/10.1186/s12885-021-09137-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8722338/
https://www.ncbi.nlm.nih.gov/pubmed/34980019
http://dx.doi.org/10.1186/s12885-021-09137-0

Ejemplares similares